These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24275677)

  • 21. Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study.
    Bjørnerem Å; Ghasem-Zadeh A; Bui M; Wang X; Rantzau C; Nguyen TV; Hopper JL; Zebaze R; Seeman E
    Bone; 2011 Dec; 49(6):1125-30. PubMed ID: 21872686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study.
    Zebaze RM; Ghasem-Zadeh A; Bohte A; Iuliano-Burns S; Mirams M; Price RI; Mackie EJ; Seeman E
    Lancet; 2010 May; 375(9727):1729-36. PubMed ID: 20472174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study.
    Brown JP; Dempster DW; Ding B; Dent-Acosta R; San Martin J; Grauer A; Wagman RB; Zanchetta J
    J Bone Miner Res; 2011 Nov; 26(11):2737-44. PubMed ID: 21735475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
    Haider IT; Sawatsky A; Zhu Y; Page R; Kostenuik PJ; Boyd SK; Edwards WB
    Bone; 2022 Nov; 164():116517. PubMed ID: 35961611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment.
    Butscheidt S; Rolvien T; Vettorazzi E; Frieling I
    Bone; 2018 Sep; 114():246-251. PubMed ID: 29960080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Menopause-Related Appendicular Bone Loss is Mainly Cortical and Results in Increased Cortical Porosity.
    Bjørnerem Å; Wang X; Bui M; Ghasem-Zadeh A; Hopper JL; Zebaze R; Seeman E
    J Bone Miner Res; 2018 Apr; 33(4):598-605. PubMed ID: 29218771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is cortical bone hip? What determines cortical bone properties?
    Epstein S
    Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
    Reid IR; Miller PD; Brown JP; Kendler DL; Fahrleitner-Pammer A; Valter I; Maasalu K; Bolognese MA; Woodson G; Bone H; Ding B; Wagman RB; San Martin J; Ominsky MS; Dempster DW;
    J Bone Miner Res; 2010 Oct; 25(10):2256-65. PubMed ID: 20533525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
    Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
    J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension.
    Brown JP; Reid IR; Wagman RB; Kendler D; Miller PD; Jensen JE; Bolognese MA; Daizadeh N; Valter I; Zerbini CA; Dempster DW
    J Bone Miner Res; 2014 Sep; 29(9):2051-6. PubMed ID: 24692050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.
    Chavassieux P; Portero-Muzy N; Roux JP; Horlait S; Dempster DW; Wang A; Wagman RB; Chapurlat R
    J Bone Miner Res; 2019 Apr; 34(4):626-631. PubMed ID: 30601581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. X-ray-verified fractures are associated with finite element analysis-derived bone strength and trabecular microstructure in young adult men.
    Rudäng R; Darelid A; Nilsson M; Mellström D; Ohlsson C; Lorentzon M
    J Bone Miner Res; 2013 Nov; 28(11):2305-16. PubMed ID: 23658040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis.
    Ostertag A; Cohen-Solal M; Audran M; Legrand E; Marty C; Chappard D; de Vernejoul MC
    Bone; 2009 Mar; 44(3):413-7. PubMed ID: 19071239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
    Iolascon G; Resmini G; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.